Screener / SEC EDGAR /CIK 0001674862 /10-K filed Nov 20, 2025, compared with Nov 18, 2024 /Numbers from the XBRL of the 10-Ks
NYSE Industrials · Chemicals & Allied Products

Ashland Inc. ASH

Compare with peers Embed
SEC comment letters, last 20 years

5 reviews of ASH's filings by SEC staff

UPLOAD and CORRESP
Reviews 5 latest letter Mar 1, 2023
Questions asked 12 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 6 UPLOAD
  2. 2. Questions in them 12 numbered comments
  3. 3. Company replies 5 CORRESP
  4. 4. Reviews closed 4 of 5 closing letter

Half the closed reviews took 23 days or less from the first letter to the closing letter.

Form 10-K

2023-03-01 to 2023-03-14 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2023-03-14
Non-GAAP measuresLiquidity and cashResults discussion (MD&A)Critical estimatesLegal and contingencies
After reviewing your response to these comments, we may have additional comments. Liquidity · Free cash flow and other liquidity resources, page M-27
SEC asked (1)
Please present the most directly comparable GAAP measure to the non-GAAP measure "ongoing free cash flow conversion". Refer to footnote 27 of the SEC Final Rule Release Number 33-8176. Additionally, disclose why management believes the presentation of this measure provides useful information to investors, and to the extent material, disclose the additional purposes, if any, for which management uses the measure.
Rest of the question

Refer to Item 10(e)(1)(i) of Regulation S-K.

ASH answered
Ashland’s use of non-GAAP measures were disclosed on pages M-12 and M-13 within the Form 10-K for Fiscal Year Ended September 30, 2022 and the reconciliations for free cash flow and other liquidity resource disclosures were on pages M-27 and M-28. Within those disclosures, Ashland has provided a quantitative reconciliation for both “Adjusted EBITDA” and “Ongoing free cash flow”.
Rest of the answer

“Ongoing free cash flow conversion” is the percentage derived from “Ongoing free cash flow” divided by “Adjusted EBITDA”.

In response to the Staff’s comment, Ashland will provide the supplemental disclosures as illustrated below. We will also enhance our disclosures for why management believes the presentation of “ongoing free cash flow conversion” provides useful information to investors.

The additional disclosure presentation changes have been bolded and underlined for ease of reference. Ashland will begin making these supplemental disclosures beginning with our Quarterly Report on Form 10-Q for the March 31, 2023 period.

Page M-12 of Form 10-K for Fiscal Year Ended September 30, 2022

Use of non-GAAP measures

The free cash flow metric enables Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, free cash flow and ongoing free cash flow includes the impact of capital expenditures from continuing operations and other significant items impacting cash flow, providing a more complete picture of current and future cash generation. Free cash flow, ongoing free cash flow and free cash flow conversion are non-GAAP liquidity measures that Ashland believes provide useful information to management and investors about Ashland’s ability to convert Adjusted EBITDA to ongoing free cash flow. These liquidity measures are used regularly by Ashland’s stakeholders and industry peers to measure the efficiency at producing cash from regular business activities. Free cash flow, ongoing free cash flow and free cash flow conversion have certain limitations, including that they do not reflect adjustments for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.

Page M-27 of Form 10-K for Fiscal Year Ended September 30, 2022

Free cash flow and other liquidity resources

The following represents Ashland’s calculation of free cash flow and ongoing free cash flow for the disclosed periods. Free cash flow does not reflect adjustments for certain non-discretionary cash flows such as mandatory debt repayments.

September 30

(In millions)

2022

2021

2020

Cash flows provided by operating activities from continuing operations

$

193

466

227

Less:

Additions to property, plant and equipment

(113

)

(105

(133

Free cash flow

361

Cash (inflows) outflows from U.S. Accounts Receivable Sales Program (a)

(17

(92

—

Restructuring-related payments (b)

Environmental and related litigation payments (c)

Ongoing free cash flow

127

351

153

Net income

927

220

(508)

Adjusted EBITDA (d)

590

495

449

Operating cash flow conversion (e)

%

212 not meaningful

Ongoing free cash flow conversion (f)

(a) Represents activity associated with the U.S. Accounts Receivable Sales Program impacting each period presented.

(b) Restructuring payments incurred during each period.

(c) Represents cash outflows associated with environmental and related litigation payments which will be reimbursed by the environmental trust.

(d) See adjusted EBITDA reconciliation.

(e) Operating cash flow conversion is defined as Cash flows provided by operating activities from continuing operations divided by Net income.

(f) Ongoing free cash flow conversion is defined as Ongoing free cash flow divided by Adjusted EBITDA.

Read in the reply
In its next report

First report after the company's reply of Mar 10, 2023: 10-Q filed May 3, 2023 ↗, against the 10-Q filed Feb 1, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Critical Accounting Policies · Asbestos litigation, page M-36
SEC asked (2)
We note that asbestos-related liabilities are now based on a 40-year model instead of a 50year model. Please disclose this change, the reason for the change, and if material, any change in estimates that resulted from the change. Refer to Item 303(b)(3) of Regulation S-K.
ASH answered
Ashland records the amount it believes to be the best estimate of future payments for asbestos litigation defense and claim settlement costs based on the results of a non-inflated, non-discounted model that extends to 2061. Ashland has consistently used this model for the last several years.

Each year that passes brings Ashland one year closer to the expected end of the forecasted time period.
Rest of the answer

At September 30, 2022, Ashland updated its disclosure to indicate “an approximate 40 year model” to bring greater precision to the disclosures that were otherwise utilized in the prior year 2021 Form 10-K. In our prior year 2021 Form 10-K, the disclosures within our critical accounting estimate indicated an “approximate 50-year model” or “models ranging from approximately 40 to 50 year periods” in various places.

To provide increased clarity regarding our asbestos litigation disclosures, in future filings we will add the following supplemental language to both our Critical Accounting Policies - Asbestos Litigation and Note N of Notes to Consolidated Financial Statements: “While the timeframe used in Ashland’s models for projecting asbestos liabilities generally decreases over time based on the expected lifetime of the liabilities, these models have been consistently applied within all periods presented.”

******

We believe that the information contained in this letter is responsive to the Comments in the Comment Letter.

Please acknowledge receipt of this response letter by electronic confirmation.

Read in the reply
In its next report

First report after the company's reply of Mar 10, 2023: 10-Q filed May 3, 2023 ↗, against the 10-Q filed Feb 1, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2023-03-14

Form 10-K

2020-03-20 to 2020-04-03 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2020-04-03
Non-GAAP measuresSegmentsResults discussion (MD&A)
After reviewing your response to these comments, we may have additional comments. MD&A · Results of Operations - Consolidated Review, page M-3
SEC asked
We note your discussion and reconciliation of non-GAAP measures precedes your caption review of results on a consolidated and segment basis under GAAP. Please revise to provide prominence to your discussion and analysis of GAAP results. Refer to non- GAAP C&DI 102.10.
ASH answered
In order to provide increased prominence to our discussion and analysis of GAAP results we have provided an example of the type of prospective disclosure we will make beginning with our second quarterly report on Form 10-Q for the interim period ending March 31, 2020 and thereafter. The changes noted below utilize the 2019 Form 10-K filing information (starting with page M-3 and ending with page M-22). The additional disclosure presentation changes have been bolded and underlined for ease of reference as follows:

U.S.
Rest of the answer

Securities and Exchange Commission

RESULTS OF OPERATIONS – CONSOLIDATED REVIEW

Consolidated review

Net income

Ashland’s net income is primarily affected by results within operating income, net interest and other financing expense, net loss on acquisitions and divestitures, income taxes, discontinued operations and other significant events or transactions that are unusual or nonrecurring. Net income also includes Ashland’s adjustment for the immediate recognition of the change in the fair value of the plan assets and net actuarial gains and losses for defined benefit pension plans and other postretirement benefit plans for each fiscal year.

Key financial results for 2019, 2018 and 2017 included the following:

•

Ashland’s net income attributable to Ashland amounted to income of $505 million in 2019, $114 million in 2018, and $1 million in 2017, or $8.03, $1.79 and $0.01 diluted earnings per share, respectively.

Ashland’s net income attributable to noncontrolling interest amounted to $27 million during 2017 and reflects the noncontrolling interest of Valvoline Inc. for the period after the IPO close on September 28, 2016 and before the final separation occurred on May 12, 2017.

Discontinued operations, which are reported net of taxes, resulted in income of $481 million, $95 million and $208 million during 2019, 2018 and 2017, respectively. The activity within discontinued operations includes the gain on the disposal of the Composites segment (excluding the Maleic business) and the Intermediates and Solvents Marl facility in 2019, the operating results of the Composites segment (including the Maleic business) and the Intermediates and Solvents Marl facility for all periods reported, and Valvoline Inc. for the period in fiscal year 2017 prior to the final separation on May 12, 2017. Discontinued operations also includes adjustments related to other retained liabilities for previously divested businesses within discontinued operations.

Results from continuing operations, which excludes results from discontinued operations, amounted to income of $24 million in 2019, $19 million in 2018 and a loss of $180 million in 2017.

The effective income tax expense rate of 66% for 2019, income tax benefit rate of 73% for 2018, and income tax benefit rate of 8% for 2017, were significantly impacted by certain tax specific key items and tax discrete items.

Ashland incurred pretax net interest and other financing expense of $99 million, $102 million and $229 million during 2019, 2018 and 2017, respectively, and was impacted by debt principal payments and certain charges associated with debt financing activity during each year.

Other net periodic benefit income (costs) totaled income of $5 million and $15 million during 2019 and 2018, respectively, and costs of $6 million during 2017.

Net loss on acquisitions and divestitures totaled $2 million, $4 million and $10 million during 2019, 2018 and 2017, respectively.

Operating income amounted to income of $166 million, $102 million and $49 million in 2019, 2018 and 2017, respectively.

For further information on the items reported above, see the discussion in the comparative Statements of Consolidated Comprehensive Income (Loss) caption review analysis.

Operating income

Operating income amounted to income of $166 million, $102 million and $49 million in 2019, 2018 and 2017, respectively. The current and prior years’ operating income included certain key items that were excluded to arrive at Adjusted EBITDA and are quantified in the table below in the “EBITDA and Adjusted EBITDA” section. These operating key items for the applicable periods are summarized as follows:

Restructuring, separation and other costs - Ashland periodically implements company-wide restructuring programs related to acquisitions, divestitures and other cost reduction programs in order to enhance profitability through streamlined operations and an improved overall cost structure. Ashland often incurs severance, facility and integration costs associated with these programs. See Notes C, D and F in the Notes to Consolidated Financial Statements for further information. Also included within this key item category are separation costs incurred as a result of the separation from Valvoline, which primarily related to transaction, consulting and legal fees. See Note B of the Notes to Consolidated Financial Statements for more information on the separation of Valvoline.

Accelerated depreciation – As a result of various restructuring activities at certain office facilities and manufacturing plants, Ashland recorded accelerated depreciation due to changes in the expected useful life of certain property, plant and equipment. See Note H of the Notes to Consolidated Financial Statements for more information.

Proxy costs – Ashland incurred significant consulting and other costs associated with the 2019 Annual Meeting of Stockholders and agreement with the Cruiser Group (as defined in the agreement).

Environmental reserve adjustments – Ashland is subject to various federal, state and local environmental laws and regulations that require environmental assessment or remediation efforts (collectively environmental remediation) at multiple locations. As a result of these activities, Ashland recorded non-cash adjustments during each year to its environmental liabilities and receivables related to previously divested businesses or non-operational sites. See Note O of the Notes to Consolidated Financial Statements for more information.

Asset impairments – Consistent with historical policies and U.S. GAAP provisions, Ashland recognizes assets at fair value less cost to sell which resulted in impairment charges to certain assets during 2019 and 2018. The charges during 2018 primarily related to the impairment of an office facility as a result of a company-wide restructuring program. See Note F of the Notes to Consolidated Financial Statements for more information.

Tax indemnity expense – During 2019 and 2018, Ashland recorded an adjustment to a tax indemnity receivable that was associated with the acquisition of Pharmachem.

Legal settlement/reserve – Ashland recorded adjustments related to settlements and/or reserves for certain legal matters.

Unplanned plant shutdowns – During 2019 and 2017, Ashland incurred costs related to temporary shutdowns as follows: (a) for the Specialty Ingredients Parlin facility as a result of force majeure contract issues in 2019 and (b) from a Specialty Ingredients manufacturing plant due to a hurricane in 2017.

Inventory fair value adjustment – During 2017, Ashland recorded non-cash charges related to the fair value adjustment of inventory acquired from Pharmachem at the date of acquisition. See Note C for more information on the acquisition of Pharmachem.

Operating income for 2019, 2018 and 2017 included depreciation and amortization of $289 million, $277 million and $265 million, respectively (which includes accelerated depreciation of $39 million, $14 million, and $19 million, respectively, for each year).

Non-operating key items affecting EBITDA

During the current and prior years, there were certain key items that were not included in operating income but were excluded to arrive at Adjusted EBITDA and are quantified in the table below in the

“EBITDA and Adjusted EBITDA” section. These non-operating key items for the applicable periods are summarized as follows:

Net loss on acquisitions and divestitures – Ashland recorded a loss on certain divestitures during each year and incurred certain transaction costs associated with the acquisition of Pharmachem during 2017. See Notes C and D of the Notes to Consolidated Financial Statements for more information on these acquisitions and divestitures.

Loss (gain) on pension and other postretirement plan remeasurements - Ashland recognized actuarial gains and losses for defined benefit pension and other postretirement benefit plans annually in the fourth quarter of each fiscal year and whenever a plan is determined to qualify for a remeasurement during a fiscal year. See Note N of the Notes to Consolidated Financial Statements for more information.

Statements of Consolidated Comprehensive Income (Loss) – caption review

A comparative analysis of the Statements of Consolidated Comprehensive Income (Loss) by caption is provided as follows for the years ended September 30, 2019, 2018 and 2017.

2019

2018

(In millions)

2017 change

Sales

$

2,493

2,589

2,309

(96

)

280

The following table provides a reconciliation of the change in sales between fiscal years 2019 and 2018 and between fiscal years 2018 and 2017.

2019 change

2018 change

Volume/product mix

(58

Currency exchange

(45

Acquisitions and Divestitures (including plant realignment)

(11

107

Pricing

Change in sales

Sales for 2019 decreased $96 million, or 4%, compared to 2018. Unfavorable volume/product mix, foreign currency exchange and acquisitions and divestitures decreased sales by $58 million, $45 million and $11 million, respectively. These decreases were partially offset by product pricing which increased sales by $18 million.

Sales for 2018 increased $280 million, or 12%, compared to 2017. The acquisition of Pharmachem within the Specialty Ingredients reportable segment increased sales by $140 million while the net impact of other acquisitions and divestitures decreased sales by $33 million. Improved volume, higher pricing and favorable foreign currency increased sales by $88 million, $40 million and $45 million, respectively.

Cost of sales

1,726

1,580

—

146

Gross profit as a percent of sales

30.8

%

33.3

31.6

Fluctuations in cost of sales are driven primarily by raw material prices, volume and changes in product mix, currency exchange, acquisitions and divestitures and other certain charges incurred as a result of changes or events within the businesses or restructuring activities.

The following table provides a reconciliation of the changes in cost of sales between fiscal years 2019 and 2018 and between fiscal years 2018 and 2017.

(27

(23

Acquisitions and divestitures (including plant realignment)

Accelerated depreciation

(13

Production costs

Unplanned plant shutdowns

(4

Inventory fair value adjustment

(7

Change in cost of sales

Cost of sales for 2019 was flat compared to 2018. Accelerated depreciation, higher production costs and charges for unplanned plant shutdowns increased cost of sales by $39 million, $14 million and $8 million, respectively. Those increases were offset by declines in volume and product mix, currency exchange and the net impact of acquisitions and divestitures which decreased cost of sales by $27 million, $23 million and $11 million, respectively.

Cost of sales for 2018 increased $146 million, or 9%, compared to 2017. The Pharmachem acquisition increased cost of sales by $101 million, while the net impact of other acquisitions and divestitures decreased cost of sales by $29 million. Changes in volume and product mix and higher production costs increased cost of sales by $54 million and $20 million, respectively. Unfavorable currency exchange increased cost of sales by $24 million. Charges for accelerated depreciation, unplanned plant shutdowns and inventory fair value adjustments decreased cost of sales by $13 million, $4 million and $7 million, respectively.

Selling, general and administrative expense

539

692

610

(153

As a percent of sales

21.6

26.7

26.4

Selling, general and administrative expense for 2019 decreased $153 million compared to 2018, with expenses as a percent of sales decreasing 5.1 percentage points. Key drivers of the fluctuation in selling, general and administrative expense compared to 2018 were:

$27 million and $60 million in net environmental-related expenses during 2019 and 2018, respectively (see Note O for more information);

$43 million and $83 million of key items for restructuring, separation and other costs during the current and prior year, respectively, comprised of the following:

o

$43 million and $56 million of severance, lease abandonment and other restructuring costs related to company-wide cost-savings initiatives during 2019 and 2018, respectively;

$10 million of costs related to the separation of Valvoline during 2018;

$8 million of accelerated depreciation related to the planned closure of an office building during 2018; and

$9 million of Pharmachem integration costs during 2018;

$16 million of asset impairment charges during 2018;

$4 million of consulting and other costs associated with the proxy contest during 2019;

Lower variable compensation of $21 million during 2019;

Favorable currency exchange of $9 million as well as achieved cost savings during 2019.

Selling, general and administrative expense for 2018 increased $82 million compared to 2017, while expenses as a percent of sales increased 0.3 percentage points. Key drivers of the fluctuation in selling, general and administrative expense compared to 2017 were:

$75 million and $86 million of restructuring, separation and other costs during 2018 and 2017, respectively, comprised of the following:

$56 million of severance, lease abandonment and other restructuring costs related to company-wide cost-savings initiatives during 2018;

$10 million of costs related to the separation of Valvoline during 2018 compared to $82 million during 2017; and

$9 million of Pharmachem integration costs during 2018 compared to $4 million during 2017;

$60 million and $21 million in net environmental-related expenses during 2018 and 2017, respectively;

$23 million of incremental costs related to Pharmachem’s operations in 2018;

$8 million increase during 2018 due to foreign currency exchange; and

$8 million of accelerated depreciation related to the closure of an office building during 2018 compared to $3 million during 2017.

Research and development expense

Research and development expense decreased $7 million in 2019 compared to 2018 primarily due to the overall company-wide cost reduction program. The 2018 expense remained relatively consistent compared to 2017.

Equity and other income

Equity income

Other income

Total equity and other income remained relatively consistent during each year.

Net interest and other expense (income)

Interest expense

114

116

227

(2

(111

Interest income

Loss (income) from restricted investments

(17

(14

(3

Other financing costs

102

229

(127

Net interest and other financing expense decreased $3 million in 2019 compared to 2018. The current year decrease in interest expense was primarily due to lower debt levels during 2019 compared to 2018. This decrease was partially offset by $6 million of accelerated debt issuance costs related to the early repayments of term loans. The investment securities income of $17 million compared to $14 million in 2018 represents investment income related to restricted investments discussed in Note G of the Notes to Consolidated Financial Statements. Interest income and other financing costs were relatively consistent.

Net interest and other financing expense decreased $127 million in 2018 compared to 2017. The decrease in interest expense from 2017 to 2018 was primarily due to 2017 including $92 million of accelerated accretion related to the December 2016 tender offer of the 2029 notes. In addition, there was also interest expense of $9 million in 2018 related to accelerated debt issuance costs associated with 2017 financing activity, which was comprised of $7 million of accelerated amortization of previously capitalized debt issuance costs and $2 million of new debt issuance costs immediately recognized. Interest expense in 2018 included $1 million of charges for new debt issuance costs incurred with the re-pricing of the 2017 term loan B facility. The investment securities income of $14 million in 2018 compared to $11 million in 2017 represents investment income related to restricted investments discussed in Note G of the Notes to Consolidated Financial Statements. The 2018 decrease in other financing costs was primarily due to a net $11 million charge during 2017 related to early redemption premium payments and bondholder consent fees for senior notes due 2018 and 2022, partially offset by a net gain related to the repayment of notes due 2029.

Other net periodic benefit income (costs)

(6

(10

Other net periodic benefit income (costs) during 2019 primarily included an $11 million loss on pension and other postretirement plan remeasurements, offset by a curtailment gain of $18 million due to the settlement of a non-U.S. pension plan in 2019. 2019 also included an $12 million charge for interest cost, partially offset by a $10 million expected return on plan assets.

Other net periodic benefit income (costs) during 2018 primarily included a gain on pension and other postretirement plan remeasurements of $14 million and an expected return on plan assets of $12 million, offset by interest cost of $11 million.

Other net periodic benefit income (costs) during 2017 primarily included interest cost of $10 million and a loss on pension and other postretirement plan remeasurements of $8 million, partially offset by an expected return on plan assets of $12 million.

Net loss on acquisitions and divestitures

Net loss on acquisitions and divestitures during 2019 primarily included a loss of $2 million related to the impairment of an investment offset by a gain on sale of a manufacturing facility, along with post-closing adjustments related to other previous divestitures.

Net loss on acquisitions and divestitures during 2018 primarily included a loss of $2 million related to the sale of a manufacturing facility, along with post-closing adjustments related to other previous divestitures.

Net loss on acquisitions and divestitures during 2017 included a net loss of $5 million from the acquisition of Pharmachem, a loss of $4 million recognized for the Specialty Ingredients joint venture divestiture in China and a loss of $1 million due to post-closing adjustments related to other previous divestitures.

Income tax expense (benefit)

(8

(16

Effective tax rate

(73

)%

The 2019 effective tax rate was impacted by jurisdictional income mix, restructuring activities, and the U.S. tax reform.

The 2018 effective tax rate was impacted by jurisdictional income mix and restructuring activities, while the impact of U.S. tax reform and other items netted together to have an insignificant impact.

The 2017 effective tax rate was impacted by jurisdictional income mix, tax expense related to deemed dividend inclusions and a tax benefit for the reversal of a valuation allowance related to the utilization of foreign tax credits.

Adjusted income tax expense (benefit)

Key items are defined as the financial effects from significant transactions that may have caused short-term fluctuations in net income and/or operating income which Ashland believes do not accurately reflect Ashland’s underlying business performance and trends. Tax specific key items are defined as the financial effects from tax specific financial transactions, tax law changes or other matters that fall within the definition of key items as previously described. The effective tax rate, excluding key items, which is a non-GAAP measure, has been prepared to illustrate the ongoing tax effects of Ashland’s operations. Management believes investors and analysts use this financial measure in assessing Ashland's business performance and that presenting this non-GAAP measure on a consolidated basis assists investors in better understanding Ashland’s ongoing business performance and enhancing their ability to compare period-to-period financial results.

The effective tax rates during 2019, 2018 and 2017 were significantly impacted by the following tax specific key items:

Deferred tax rate changes - Includes the impact from the remeasurement of Ashland’s domestic deferred tax balances resulting from the enactment of the Tax Act as well as the impact from deferred rate changes for other jurisdictions during 2019 and 2018;

One-time transition tax - Includes the one-time transition tax resulting from the enactment of the Tax Act during 2019 and 2018;

Uncertain tax position - Includes the impact from the settlement of uncertain tax positions with various tax authorities during 2019 and 2018;

Restructuring and separation activity - Includes the impact from company-wide restructuring activities during 2018 and the separation of Valvoline during 2017. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments;

Other tax reform - Includes the impact from other tax law changes resulting from the enactment of the Tax Act during 2019 and 2018. These adjustments include the impact from the deductibility of compensation items and miscellaneous state tax items;

Valuation allowances - Includes the impact from net operating loss and foreign tax credit valuation allowances during 2019, 2018 and 2017; and

Foreign dividends - Includes the impact from a significant deemed dividend inclusion in the U.S. during 2017. This deemed dividend transaction allowed Ashland to utilize foreign tax credit carryforwards which may have otherwise expired. This transaction was driven in part by projected changes to Ashland’s business and tax profile as a result of the Valvoline separation.

The following table is a calculation of the effective tax rate, excluding the impact of these key items:

Income (loss) from continuing operations before income taxes

(196

Key items (pre-tax) (a)

112

140

263

Adjusted income from continuing operations

182

151

Income tax rate adjustments:

Tax effect of key items (b)

Tax specific key items: (c)

Deferred tax rate changes

139

One-time transition tax

(28

(128

Uncertain tax positions

Restructuring and separation activity

(12

(36

Other tax reform related activity

Valuation allowances

Foreign dividends

(87

Total income tax rate adjustments

(21

Effective tax rate, excluding key items (Non-GAAP)

(a)

See Adjusted EBITDA reconciliation table previously disclosed in this Management, Discussion and Analysis for a summary of the key items, before tax.

(b)

The tax rate specific to the jurisdiction in which the key item originates is used to calculate the tax effect of key items.

(c)

For additional information on the effect that these tax specific key items had on EPS, see the Adjusted Diluted EPS table previously disclosed in this Management Discussion and Analysis.

The following table provides a reconciliation of tax specific key items within the statutory federal income tax with the provision for income taxes summary disclosed in Note M of the Notes to Consolidated Financial Statements.

Tax effect of key items computed at applicable statutory rate

Tax reform

(30

(9

(1

Foreign dividend, deemed inclusions and other restructuring

Foreign tax credits

(44

Valuation allowance changes (a)

State taxes

Other items

Includes $14 million of charges during 2017 that were included in the “Restructuring and separation activity” line in previous table, which is an activity-based reconciliation.

Income (loss) from discontinued operations (net of taxes)

Composites and Marl Facility

Asbestos-related litigation

(25

Water Technologies

Distribution

Valvoline

159

(160

Gain on disposal of discontinued operations

Composites/Marl facility

372

481

208

386

(113

As a result of the divestiture of the Composites segment (including the Maleic business) and Marl facility, the related operating results have been reflected as discontinued operations (net of tax) within the Statements of Consolidated Comprehensive Income (Loss). See Note E for more information on this divestiture. In 2019, the sales and pre-tax operating income included in discontinued operations were $1,012 million and $145 million, respectively. In 2018, the sales and pre-tax operating income included in discontinued operations were $1,154 million and $125 million, respectively. In 2017, the sales and pre-tax operating income included in discontinued operations were $951 million and $97 million, respectively. A $372 million gain on disposal was recorded in the fourth quarter associated with the August 30, 2019 closing of the Composites business (excluding the Maleic business) and the Marl facility with INEOS.

Asbestos-related activity during 2019, 2018 and 2017 included after-tax net adjustments to the asbestos reserves and receivables of zero, $13 million of income and $25 million of expense, respectively, including the adjustments for the annual update.

The activity for Water Technologies and Distribution during 2019, 2018 and 2017 was related to post-closing adjustments.

The Valvoline activity within 2019 and 2018 primarily represents subsequent adjustments that were made in conjunction with the Tax Matters Agreement. Prior to the full separation of Valvoline Inc. on

May 12, 2017, the operating results related to Valvoline Inc., including the operating results of the former Valvoline reportable segment, have been reflected as discontinued operations (net of tax) within the Statements of Consolidated Comprehensive Income (Loss) for 2017. Valvoline’s sales included in discontinued operations during 2017 were $1,237 million (reflective of sales until the full separation on May 12, 2017). Valvoline’s pre-tax income of discontinued operations during 2017 totaled $240 million.

Net income attributable to noncontrolling interest

Since Ashland’s ownership interest in Valvoline Inc. was approximately 83% after completing the IPO on September 28, 2016 and before the distribution of its remaining shares of Valvoline on May 12, 2017, the amount of net income attributable to the outside stockholders’ approximately 17% noncontrolling interest in Valvoline Inc. was presented within this caption in the Statements of Consolidated Comprehensive Income (Loss) for 2017.

Other comprehensive income (loss)

A comparative analysis of the components of other comprehensive income (loss) is provided below for the last three fiscal years ended September 30.

Other comprehensive income (loss) (net of taxes)

Unrealized translation gain (loss)

(80

(82

(163

Pension and postretirement obligation adjustment

(5

Net change in investment securities

(85

(69

(161

Total other comprehensive income (loss), net of tax, decreased $16 million in 2019 as compared to 2018 as a result of the following components.

In 2019, the change in unrealized gain (loss) from foreign currency translation adjustments resulted in a loss of $80 million, compared to a loss of $82 million during 2018. The fluctuations in unrealized translation gains and losses were primarily due to translating foreign subsidiary financial statements from local currencies to U.S. Dollars.

The pension and postretirement obligation adjustment was $5 million during 2019 compared to zero during 2018. The adjustment during 2019 related to amortization of unrecognized prior services credits for pension and other postretirement benefit plans, net of tax, and were reclassified into net income.

Due to the adoption of new accounting guidance in 2019, unrealized gains and losses on Ashland’s equity securities are now recognized in net income rather than AOCI. See Notes A and G for more information. A $13 million gain on investment securities, net of tax, related to restricted investments, were recognized within other comprehensive income (loss) during 2018.

Total other comprehensive income (loss), net of tax, decreased $161 million in 2018 as compared to 2017 as a result of the following components.

In 2018, the change in unrealized gain (loss) from foreign currency translation adjustments resulted in a loss of $82 million, compared to a gain of $81 million during 2017. The fluctuations in unrealized translation gains and losses are primarily due to translating foreign subsidiary financial statements from local currencies to U.S. Dollars.

The pension and postretirement obligation adjustment was zero during 2018 compared to a loss of $4 million during 2017 due to unrecognized prior service credits, net of tax, relating to pension and other postretirement benefit plans were amortized and reclassified into net income.

Gains of $13 million and $15 million on restricted investments, net of tax, were recognized within other comprehensive income (loss) during 2018 and 2017, respectively.

Use of non-GAAP measures

Ashland has included within this document the following non-GAAP measures, on both a consolidated and reportable segment basis, which are not defined within U.S. GAAP and do not purport to be alternatives to net income or cash flows from operating activities as a measure of operating performance or cash flows:

EBITDA - net income (loss), plus income tax expense (benefit), net interest and other financing expenses, and depreciation and amortization.

Adjusted EBITDA - EBITDA adjusted for noncontrolling interests, discontinued operations, net gain (loss) on acquisitions and divestitures, other income and (expense) and key items (including the remeasurement gains and losses related to pension and other postretirement plans).

Adjusted EBITDA margin - Adjusted EBITDA, which can include pro forma adjustments, divided by sales.

Adjusted diluted earnings per share (EPS) - income (loss) from continuing operations, adjusted for key items, net of tax, divided by the average outstanding diluted shares for the applicable period.

Free cash flow - operating cash flows less capital expenditures and certain other adjustments as applicable.

Management believes the use of EBITDA and Adjusted EBITDA measures on a consolidated and reportable segment basis assists investors in understanding the ongoing operating performance by presenting comparable financial results between periods. Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes and certain other charges that are highly variable from year to year, EBITDA and Adjusted EBITDA provide Ashland’s investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income and operating income. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA and Adjusted EBITDA exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA and Adjusted EBITDA provide disclosure on the same basis as that used by Ashland’s management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland’s historical operating performance and its business units and provide continuity to investors for comparability purposes.

The Adjusted diluted EPS metric enables Ashland to demonstrate what effect key items have on an earnings per diluted share basis by taking income (loss) from continuing operations, adjusted for key items after tax that have been identified in the Adjusted EBITDA table, and dividing by the average outstanding diluted shares for the applicable period. Ashland’s management believes this presentation is helpful to illustrate how the key items have impacted this metric during the applicable period.

The free cash flow metric enables Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, free cash flow includes the impact of capital expenditures from continuing operations, providing a more complete picture of cash generation. Free cash flow has certain limitations, including that it does not reflect adjustment for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.

Although Ashland may provide forward-looking guidance for Adjusted EBITDA, Adjusted diluted EPS and free cash flow, Ashland is not reaffirming or providing forward-looking guidance for U.S. GAAP-reported financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items that affect these metrics such as domestic and international economic, political, legislative, regulatory and legal actions. In addition, certain economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, government fiscal policies and changes in the prices of certain key raw materials, can have a significant effect on operations and are difficult to predict with certainty.

These non-GAAP measures should be considered supplemental in nature and should not be construed as more significant than comparable measures defined by U.S. GAAP. Limitations associated with the use of these non-GAAP measures include that these measures do not present all of the amounts associated with our results as determined in accordance with U.S. GAAP. The non-GAAP measures provided are used by Ashland management and may not be determined in a manner consistent with the methodologies used by other companies. EBITDA and Adjusted EBITDA provide a supplemental presentation of Ashland’s operating performance on a consolidated and reportable segment basis. Adjusted EBITDA generally includes adjustments for items that impact comparability between periods. In addition, certain financial covenants related to Ashland’s 2017 Credit Agreement are based on similar non-GAAP measures and are defined further in the sections that reference this metric.

In accordance with U.S. GAAP, Ashland recognizes actuarial gains and losses for defined benefit pension and other postretirement benefit plans annually in the fourth quarter of each fiscal year and whenever a plan is determined to qualify for a remeasurement during a fiscal year. Actuarial gains and losses occur when actual experience differs from the estimates used to allocate the change in value of pension and other postretirement benefit plans to expense throughout the year or when assumptions change, as they may each year. Significant factors that can contribute to the recognition of actuarial gains and losses include changes in discount rates used to remeasure pension and other postretirement obligations on an annual basis or upon a qualifying remeasurement, differences between actual and expected returns on plan assets and other changes in actuarial assumptions, for example, the life expectancy of plan participants. Management believes Adjusted EBITDA, which includes the expected return on pension plan assets yet excludes both the actual return on pension plan assets and the impact of actuarial gains and losses, provides investors with a meaningful supplemental presentation of Ashland’s operating performance (see the Adjusted EBITDA reconciliation table on page M-8 for additional details on exact amounts included within this non-GAAP measure related to pension and other postretirement plans). Management believes these actuarial gains and losses are primarily financing activities that are more reflective of changes in current conditions in global financial markets (and in particular interest rates) that are not directly related to the underlying business. For further information on the actuarial assumptions and plan assets referenced above, see Note N of the Notes to Consolidated Financial Statements.

EBITDA and Adjusted EBITDA

EBITDA totaled $900 million, $471 million and $487 million for 2019, 2018 and 2017, respectively. EBITDA and Adjusted EBITDA results in the following table have been prepared to illustrate the ongoing effects of Ashland’s operations, which exclude certain key items previously described. Management believes the use of such non-GAAP measures on a consolidated and reportable segment basis assists investors in understanding the ongoing operating performance by presenting the financial results between periods on a more comparable basis.

Net income (loss)

505

Net interest and other financing expense

Depreciation and amortization (a)

250

246

EBITDA

900

471

487

Income from discontinued operations (net of taxes)

(481

(95

(208

Key items included in EBITDA:

Restructuring, separation and other costs (b)

Proxy costs

Environmental reserve adjustments

Asset impairments

Tax indemnity expense

Net loss on acquisitions and divestitures (c)

Loss (gain) on pension and other postretirement plan remeasurements

Legal settlement/reserve

Total key items included in EBITDA

113

Adjusted EBITDA (d)

532

515

430

Unrealized gain on securities (e)

Debt refinancing costs (f)

Total key items, before tax

Excludes $39 million, $14 million and $19 million of accelerated depreciation during 2019, 2018 and 2017, respectively.

Includes impairments of $8 million during 2019.

Excludes expense of $3 million, $2 million and $9 million during 2019, 2018 and 2017, respectively, related to ongoing adjustments of previous divestiture transactions.

(d)

Includes $9 million, $8 million and $7 million during 2019, 2018 and 2017, respectively, of net periodic pension and other postretirement costs (income) recognized ratably through the fiscal year. These costs (income) are comprised of service cost, interest cost, expected return on plan assets, and amortization of prior service credit and are disclosed in further detail in Note N of the Notes to Consolidated Financial Statements.

(e)

Due to the adoption of new accounting guidance in 2019, the unrealized (gains) losses on certain investment securities directly impact earnings and are recorded within the net interest and other expense caption on the Statements of Consolidated Comprehensive Income (Loss). See Note A of the Notes to Consolidated Financial Statements for more information.

(f)

Debt refinancing costs during 2019 included a $6 million debt issuance costs amortization charge for the early repayment of term loans A and B. Debt refinancing costs during 2018 primarily included a $1 million charge for new debt issuance costs incurred with the re-pricing of the term loan B facility. Debt refinancing costs during 2017 included $92 million of accelerated accretion from the tender offer of the 2029 notes, a $16 million charge for early redemption premium payments and bondholder consent fees for senior notes due 2018 and 2022, a $9 million charge for debt issuance costs resulting from financing activity for the 2017 Credit Agreement and a net gain of $5 million related to the repayment of notes due 2029. All debt refinancing costs were recorded within the net interest and other financing expense caption on the Statements of Consolidated Comprehensive Income (Loss). See Note J of the Notes to Consolidated Financial Statements for more information.

Diluted EPS and Adjusted Diluted EPS

The following table reflects the U.S. GAAP calculation for the income (loss) from continuing operations adjusted for the cumulative diluted EPS effect for key items after tax that have been identified in the Adjusted EBITDA table in the previous section. Key items are defined as the financial effects from significant transactions that may have caused short-term fluctuations in net income and/or operating income which Ashland believes do not accurately reflect Ashland’s underlying business performance and trends. The Adjusted Diluted EPS for the income (loss) from continuing operations in the following table has been prepared to illustrate the ongoing effects of Ashland’s operations. Management believes investors and analysts use this financial measure in assessing Ashland's business performance and that presenting this non-GAAP measure on a consolidated basis assists investors in better understanding Ashland’s ongoing business performance and enhancing their ability to compare period-to-period financial results.

Diluted EPS from continuing operations (as reported)

0.39

0.29

(2.90

Key items, before tax:

Restructuring, separation and other costs (including accelerated depreciation)

1.42

1.43

1.70

0.07

0.24

0.68

0.15

0.25

Loss (gain) on pension and other postretirement plan remeasurements

(0.11

(0.22

0.13

0.10

0.08

0.05

0.04

0.16

(0.07

0.03

Unrealized (gain) loss on securities

0.11

Debt refinancing costs

0.09

0.02

1.78

Key items, before tax

2.21

4.20

Tax effect of key items (a)

(0.47

(1.39

Key items, after tax

1.56

1.74

2.81

Tax specific key items:

(2.18

0.44

2.00

(0.09

(0.39

0.19

0.56

0.28

(0.02

0.17

(0.33

1.38

Tax specific key items (b)

0.55

1.33

Total key items

2.11

1.90

4.14

Adjusted diluted EPS from continuing operations (non-GAAP)

2.50

2.19

1.24

Represents the diluted EPS impact from the tax effect of the key items that are previously identified above.

Represents the diluted EPS impact from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. For additional explanation of these tax specific key items, see the income tax expense (benefit) discussion within the following caption review section.

RESULTS OF OPERATIONS – REPORTABLE SEGMENT REVIEW

Ashland’s operations are managed within the following two reportable segments: Specialty Ingredients and Intermediates and Solvents. Results of Ashland’s reportable segments are presented based on its management and internal accounting structure. The structure is specific to Ashland; therefore, the financial results of Ashland’s reportable segments are not necessarily comparable with similar information for other comparable companies. Ashland allocates all costs to its reportable segments except for certain significant company-wide restructuring activities and other costs or adjustments that relate to former businesses that Ashland no longer operates. The service cost component of pension and other postretirement benefits costs is allocated to each reportable segment on a ratable basis; while the remaining components of pension and other postretirement benefits costs are recorded within the other net periodic benefit income (costs) caption on the Statements of Consolidated Comprehensive Income (Loss). Ashland refines its expense allocation methodologies to the reportable segments from time to time as internal accounting practices are improved, more refined information becomes available and the industry or market changes. Significant revisions to Ashland’s methodologies are adjusted for all segments on a retrospective basis.

The following table shows sales, operating income, depreciation and amortization and statistical operating information by reportable segment for each of the last three years ended September 30.

Specialty Ingredients

2,382

2,470

2,216

Intermediates and Solvents

111

119

Operating income (loss)

272

314

233

Unallocated and Other

(122

(229

(178

166

Depreciation and amortization

273

252

243

289

277

265

Operating information

Specialty Ingredients (a)

Sales per shipping day

9.4

9.8

8.8

Metric tons sold (thousands)

317.2

324.7

31.1

33.8

32.7

Intermediates and Solvents (a)

0.4

0.5

35.3

37.5

34.9

23.1

23.0

4.1

Sales are defined as sales and operating revenues. Gross profit is defined as sales, less cost of sales.

Sales by region expressed as a percentage of reportable segment sales for each of the last three fiscal years ended September 30 were as follows. Ashland includes only U.S. and Canada in its North American designation.

Sales by Geography

Specialty

Ingredients

Intermediates and Solvents

North America

Europe

Asia Pacific

Latin America & other

100

Specialty Ingredients offers industry-leading products, technologies and resources for solving formulation and product-performance challenges. Using natural, synthetic and semisynthetic polymers derived from cellulose ethers, vinyl pyrrolidones, acrylic polymers, polyester and polyurethane-based adhesives, and plant and seed extract, Specialty Ingredients offers comprehensive and innovative solutions for consumer and industrial applications.

Key customers include pharmaceutical companies; makers of personal care products, food and beverages manufacturers; makers of nutraceuticals and supplements; manufacturers of paint, coatings and construction materials; packaging and converting; and oilfield service companies.

On May 17, 2017, Ashland completed its acquisition of the stock of Pharmachem, a leading provider of quality ingredients to the global health and wellness industries and high-value differentiated products to fragrance and flavor houses. At the acquisition date, Pharmachem had approximately $300 million in annual revenues and 14 manufacturing facilities located in the United States and Mexico. New Jersey-based Pharmachem develops, manufactures and supplies custom and branded nutritional and fragrance products. See Note C of the Notes to Consolidated Financial Statements for more information.

Ashland completed the transfer of its ownership interest in a consolidated joint venture during 2017. See Note D of the Notes to Consolidated Financial Statements for information on this divestiture.

2019 compared to 2018

Specialty Ingredients’ sales decreased $88 million, or 4%, to $2,382 million in 2019. Volume/mix, unfavorable foreign currency exchange and the closures of a manufacturing plant decreased sales by $49 million, $44 million and $11 million, respectively. Improved product pricing increased sales by $16 million.

Gross profit during 2019 decreased $95 million compared to 2018. Unfavorable foreign currency exchange and the net impact of volume and mix decreased gross profit by $21 million and $28 million, respectively. The net impact of pricing and costs decreased gross profit by $46 million, which included a $42 million net impact from the following key items during 2019 and 2018:

$45 million and $3 million of costs related to restructuring activity related to certain manufacturing plants during 2019 and 2018, respectively (including $38 million of accelerated depreciation for 2019);

$2 million of unplanned plant shutdown costs for a manufacturing facility during 2019; and

$2 million of impairment of an asset during 2018.

In total, gross profit margin during 2019 decreased 2.7 percentage points to 31.1% as compared to 2018.

Selling, general and administrative expenses (which includes research and development expenses throughout the reportable segment discussion and analysis) decreased $50 million during 2019 as compared to 2018, largely due to the company-wide cost reduction program, lower employee incentive program costs and favorable foreign currency exchange. Equity and other income increased $3 million compared to 2018.

Operating income totaled $272 million for 2019 compared to $314 million in 2018. EBITDA decreased $53 million to $507 million in 2019, while Adjusted EBITDA decreased $16 million to $558 million. Operating income margin decreased 1.3 percentage points in 2019 to 11.4%. Adjusted EBITDA margin increased 0.2 percentage points in 2019 to 23.4%.

2018 compared to 2017

Specialty Ingredients’ sales increased $254 million, or 11%, to $2,470 million in 2018. The acquisition of Pharmachem increased sales by $140 million, or 6%. Volume and mix combined to increase sales by $87 million while favorable foreign currency exchange increased sales by $42 million. In addition, improved product pricing increased sales by $18 million. These increases were partially offset by a decrease of $33 million primarily related to the transfer of ownership interest in a consolidated joint venture.

Gross profit during 2018 increased $110 million compared to 2017. The acquisition of Pharmachem and improved volume and mix increased gross profit by $39 million each, while favorable foreign currency exchange increased gross profit by $18 million. Additionally, the net impact of pricing and costs increased gross profit by $18 million, which included a $24 million net impact from the following key items during 2018 and 2017:

$3 million of costs related to restructuring activity at certain manufacturing plants during 2018;

$7 million of non-cash charges related to the fair value assessment of inventory acquired from Pharmachem at the date of acquisition during 2017; and

$6 million of costs related to the temporary shutdown of a manufacturing plant due to a hurricane during 2017.

These increases to gross profit were partially offset by a decrease of $4 million related to the joint venture divestiture. In total, gross profit margin during 2018 increased 1.1 percentage points to 33.8% as compared to 2017.

Selling, general and administrative expenses increased $27 million during 2018 as compared to 2017, largely due to incremental costs of $23 million related to the acquisition of Pharmachem’s operations. The remaining increase to selling, general and administrative expense was primarily attributable to unfavorable foreign currency exchange. Equity and other income (loss) decreased $2 million compared to 2017.

Operating income totaled $314 million for 2018 compared to $233 million in 2017. EBITDA increased $98 million to $560 million in 2018, while Adjusted EBITDA increased $81 million to $574 million. Operating income margin increased 2.2 percentage points in 2018 to 12.7%. Adjusted EBITDA margin increased 1.0 percentage point in 2018 to 23.2%.

EBITDA and Adjusted EBITDA reconciliation

The EBITDA and Adjusted EBITDA amounts presented within this business section are provided as a means to enhance the understanding of financial measurements that Ashland has internally determined to be relevant measures of comparison for each segment. Each of these non-GAAP measures is defined as follows: EBITDA (operating income plus depreciation and amortization), Adjusted EBITDA (EBITDA adjusted for key items, which may include pro forma effects for significant acquisitions or divestitures, as applicable), and Adjusted EBITDA margin (Adjusted EBITDA, which may include pro forma adjustments, divided by sales or sales adjusted for pro forma results). Ashland does not allocate items to each reportable segment below operating income, such as interest expense and income taxes. As a result, reportable segment EBITDA and Adjusted EBITDA are reconciled directly to operating income since it is the most directly comparable Statements of Consolidated Comprehensive Income (Loss) caption.

The following EBITDA and Adjusted EBITDA presentation for the three annual periods is provided as a means to enhance the understanding of financial measurements that Ashland has internally determined to be relevant measures of comparison for the results of Specialty Ingredients. Adjusted EBITDA results have been prepared to illustrate the ongoing effects of Ashland’s operations, which exclude certain key items.

The key items during 2019 included $38 million of accelerated depreciation related to a planned facility closure, $10 million of costs related to restructuring activity at certain manufacturing plants, $2 million of an unplanned plant shutdown and $1 million of environmental reserve adjustments.

The key items during 2018 included $6 million of accelerated depreciation related to the termination of a contract at a manufacturing facility, $2 million of integration costs related to the acquisition of Pharmachem and $3 million of costs related to restructuring activity at certain manufacturing plants. Additional key items during 2018 included $2 million of asset impairment charges and $1 million of environmental reserve adjustments.

The key items during 2017 included $18 million of restructuring charges for the closure of a manufacturing plant and the termination of a contract at a manufacturing facility (which included $14 million of accelerated depreciation and $4 million of severance and other restructuring costs), $7 million for the revaluation of Pharmachem inventory and $6 million of charges related to an unplanned plant shutdown.

September 30

235

507

560

462

Severance and other costs

Asset impairment

Environmental reserve adjustment

Unplanned plant shutdown

Adjusted EBITDA

558

574

493

Excludes $38 million, $6 million and $14 million of accelerated depreciation during 2019, 2018 and 2017, respectively.

Intermediates and Solvents is a leading producer of 1,4 butanediol and related derivatives, including n-methylpyrrolidone. These products are used as chemical intermediates in the production of engineering polymers and polyurethanes, and as specialty process solvents in a wide array of applications including electronics, pharmaceuticals, water filtration membranes and more. Butanediol is also supplied to Ashland’s Specialty Ingredients business for use as a raw material at cost.

Intermediates and Solvents sales decreased $8 million, or 7%, to $111 million in 2019. Volume and mix combined to decrease sales by $8 million and unfavorable foreign currency exchange decreased sales by another $1 million. Lower product pricing increased sales by $1 million.

Gross profit during 2019 decreased $2 million compared to 2018. Unfavorable foreign currency exchange decreased gross profit by $1 million, while the net impact of pricing and costs decreased gross profit by an additional $1 million.

In total, gross profit margin during 2019 increased 0.1 percentage points to 23.1% as compared to 2018.

Selling, general and administrative expenses decreased $1 million during 2019 as compared to 2018.

Operating income totaled $16 million for 2019 compared to $17 million in 2018. EBITDA decreased $2 million to $29 million in 2019. Operating income margin increased 0.1 percentage point in 2019 to 14.4%. EBITDA margin of 26.1% in 2019 was flat compared to 2018.

Intermediates and Solvents’ sales increased $26 million, or 28%, to $119 million in 2018. Improved product pricing increased sales by $22 million, while volume and favorable foreign currency exchange added an additional $2 million each.

Gross profit during 2018 increased $23 million compared to 2017. Pricing and higher costs combined to increase gross profit by $19 million, while volume and mix combined to increase gross profit by $2 million. Additionally, favorable foreign currency exchange increased gross profit by $2 million. In total, gross profit margin during 2018 increased 18.9 percentage points to 23.0% as compared to 2017.

Selling, general and administrative expenses and equity and other income (loss) remained consistent as compared to 2017.

Operating income totaled $17 million for 2018 compared to a loss of $6 million in 2017. EBITDA increased $23 million to $31 million in 2018. Operating income margin increased 20.8 percentage points in 2018 to 14.3%. Adjusted EBITDA margin increased 17.5 percentage points in 2018 to 26.1%.

The following EBITDA presentation (as defined and described in the section above) for the three annual periods is provided as a means to enhance the understanding of financial measurements that Ashland has internally determined to be relevant measures of comparison for the results of Intermediates and Solvents. There were no unusual or key items that affected comparability for EBITDA during 2019, 2018 or 2017.

Unallocated and other

The following table summarizes the key components of the Unallocated and other segment’s operating income (loss) for each of the last three years ended September 30.

Restructuring activities

(139

(136

Environmental expenses

(20

Asset impairment charges

Other income (expense)

(18

Total unallocated expense

Unallocated and other recorded expense of $122 million, $229 million and $178 million for 2019, 2018, and 2017, respectively. The charges for restructuring activities of $87 million, $139 million and $136 million during 2019, 2018 and 2017, respectively, were primarily comprised of the following items:

$42 million and $49 million of severance, lease abandonment and other restructuring costs related to company-wide cost-savings initiatives during 2019 and 2018, respectively;

$4 million of impairment related to the planned sale of an office building during 2019;

$41 million, $59 million and $50 million of stranded divestiture costs during 2019, 2018 and 2017, respectively;

$10 million and $82 million of costs related to the separation of Valvoline during 2018 and 2017 respectively;

$14 million of accelerated depreciation related to the closure of an office building during 2018; and

$7 million and $4 million of integration costs related to the acquisition of Pharmachem during 2018 and 2017, respectively.

******

We believe that the information contained in this letter is responsive to the Comment in the Comment Letter.

Please acknowledge receipt of this response letter by electronic confirmation.

Read in the reply
In its next report

First report after the company's reply of Mar 26, 2020: 10-Q filed May 6, 2020 ↗, against the 10-Q filed Jan 29, 2020 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2020-04-03

Form 10-K for the year ended September 30, 2018

2019-04-30 to 2019-05-23 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2019-05-23
Income taxes
Note M - Income Taxes, page F-35
SEC asked
Please reconcile the disclosures surrounding the impact of the Tax Act you provided on page F-35 with the information you have presented in your reconciliation of the statutory federal income tax to your provision for income taxes on page F-37.
Rest of the question

Ensure that the tax reform amounts presented in the reconciliation and related footnotes are transparent such that a reader understands the impact the Tax Act had on your provision for income taxes. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

ASH answered
Net Transition Tax - $128 million (disclosed on F-35) – consisting of the following components: One-time Transition Tax expense of $187 million and other amounts related to the transition tax, including State Tax expense of $2 million, Foreign Tax Credits benefit of $46 million, Uncertain Tax Positions benefit of $9 million and Other tax benefit of $6 million;
Read in the reply
In its next report

First report after the company's reply of May 13, 2019: 10-Q filed Jul 31, 2019 ↗, against the 10-Q filed Feb 6, 2019 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2019-05-23

Ashland Global Holdings Inc. · Soliciting Materials filed pursuant to Rule 14a-12 by Cruiser Capital · Advisors, LLC, Keith M. Rosenbloom, Cruiser Capital Master Fund LP, · Metamorphosis IV LLC, Allen A. Spizzo, William H. Joyce, Patrick E. · Gottschalk, and Carol S. Eicher · Filed on November 28, 2018 · File No. 333-211719

2018-11-29 to 2018-11-29 · 1 question · 1 letter from the SEC, 0 from the company
No closing letter
SEC letter of Nov 29, 2018 ↗ no reply letter on EDGAR
Soliciting Materials
SEC asked
You state on slide 5 of your presentation that Ashland is “worth well in excess of $125+” and that it is “[p]otentially worth substantially more.” The inclusion of valuations in soliciting materials is only appropriate and consonant with Rule 14a-9 when made in good faith and on a reasonable basis and where accompanied by disclosure which facilities shareholders’ understanding of the basis for and the limitations on
Rest of the question

the projected realizable values. See Exchange Act Release No. 16833 (May 23, 1980). Please provide us with your analysis supporting your valuation of the company and confirm that in future filings in which you provide a valuation you will include a similar analysis. In addition, supplementally explain why your valuation is not so qualified and subject to such material limitations and qualifications as to make inclusion of the “$125+” figure and the next bullet point unreasonable.

ASH answered

No reply letter found.

Form 10-K

2018-02-07 to 2018-03-22 · 7 questions · 2 letters from the SEC, 2 from the company
Review closed 2018-03-22
Income taxesNon-GAAP measuresResults discussion (MD&A)
Form 10-K for the year ended September 30, 2017 · Diluted EPS and Adjusted Diluted EPS, page M-8
SEC asked (1)
Please define Key items and separately identify the significant reconciling items. Also, please see our comment below regarding the appropriateness of the tax discrete items which appear to be included in your Key items. See Table 8 in Exhibit 99.1 of your Form 8-K dated November 6, 2017.
ASH answered
Set forth below are responses from Ashland Global Holdings Inc. (“Ashland” or “we”) to the comments (the “Comments”) of the staff (the “Staff”) of the United States Securities and Exchange Commission (the “SEC”), dated February 7, 2018, concerning Ashland’s Annual Report on Form 10-K for the fiscal year ended September 30, 2017 (the “2017 Form 10-K”), Ashland’s Form 8-K dated November 6, 2017 (the “November Form 8-K”) and Ashland’s Form 8-K dated January 29, 2018 (the “January Form 8-K”). For your convenience, the responses set forth below have been put in the same order as the Comments were presented and repeat each Comment prior to the response. The Comments are highlighted in bold.
Rest of the letter

FORM 10-K FOR THE YEAR ENDED SEPTEMBER 30, 2017 Diluted EPS and Adjusted Diluted EPS, page M-8 Please define Key items and separately identify the significant reconciling items. Also, please see our comment below regarding the appropriateness of the tax discrete items which appear to be included in your Key items. See Table 8 in Exhibit 99.1 of your Form 8-K dated November 6, 2017. As requested, in future filings we will define the term “key items” in the diluted earnings per share (EPS) section preceding the table that details the adjustments to the U.S. GAAP calculation of diluted EPS. In addition, we will separately identify the effect each key item has on the adjusted diluted EPS number. The following is an example of prospective enhanced disclosures utilizing the 2017 Form 10-K filing information; we will include this enhanced disclosure in all future Form 10-Q and Form 10-K filings, beginning with our second quarter Form 10-Q filing for fiscal 2018: The following table reflects the U.S. GAAP calculation for the loss from continuing operations adjusted for the cumulative diluted EPS effect for key items after tax that have been identified in the Adjusted EBITDA table in the previous section. Key items are defined as the financial effects from significant transactions that may have caused short-term fluctuations in net income and/or operating income which Ashland believes do not accurately reflect Ashland’s underlying business performance and trends. The Adjusted EPS for the loss from continuing operations in the following table has been prepared to illustrate the ongoing effects of Ashland’s operations. Management believes investors and analysts use this financial measure in assessing Ashland's business performance and that presenting this non-GAAP measure on a consolidated basis assists investors in better understanding Ashland’s ongoing business performance and enhancing their ability to compare period-to-period financial results. Diluted EPS from continuing operations (as reported) Separation, restructuring and other costs, net Net loss on acquisitions and divestitures Adjusted Diluted EPS from continuing operations (non-GAAP) The appropriateness of the tax discrete items included as “key items” is further described below in our response to Comment #3 – Fifth Bullet. Statements of Consolidated Comprehensive Income (Loss) – caption review, page M-8 Please expand your disclosures on page M-11 to indicate how you calculated your effective tax rate (excluding key items) and why you believe this information is useful to an investor. As requested, in future filings we will expand our disclosures regarding the calculation of our effective tax rate (excluding key items) compared to the U.S. GAAP calculation of the effective tax rate. In addition, in our use of non-GAAP measures section of our Form 10-Q and Form 10-K, we will describe why we believe this information is useful to an investor. The following is an example of what this enhanced disclosure would look like in the 2017 Form 10-K filing; we will include this enhanced disclosure in all future Form 10-Q and Form 10-K filings, beginning with our second quarter Form 10-Q filing for fiscal 2018: Key items are defined as the financial effects from significant transactions that may have caused short-term fluctuations in net income and/or operating income which Ashland believes do not accurately reflect Ashland’s underlying business performance and trends. The effective tax rate (excluding key items), which is a non-GAAP measure, has been prepared to illustrate the ongoing tax effects of Ashland’s operations. Management believes investors and analysts use this financial measure in assessing Ashland’s business performance and that presenting this non-GAAP measure on a consolidated basis assists investors in better understanding Ashland’s ongoing business performance and enhancing their ability to compare period-to-period financial results. The table below is a calculation of the effective tax rate (excluding key items) which includes certain adjustments for key items. Loss from continuing operations before taxes Adjusted income from cont. operations before taxes (a) – For these adjustments a tax rate specific to the jurisdiction in which the key item originates is used. We have the following comments on your non-GAAP measures and related presentations: With reference to your Outlook section, we note that you omit the most directly comparable GAAP measures and quantitative reconciliation with respect to your forward-looking non-GAAP guidance, but you do not provide the disclosures required when the reconciliation is omitted. Please follow the guidance in Item 10(e)(1)(i)(A) of Regulation S-K and Question 102.10 of the updated Non-GAAP Compliance and Disclosure Interpretations issued on May 17, 2016; Please revise your reconciliations in Table 5 to begin with your most comparable GAAP measures; Please define “key items” and “discrete items” as used in Table 5. In this regard, we note Tables 7 and 8 refer readers back to Table 5 for information regarding these items; Please reconcile the income tax expense of discrete items to your reconciliation of the statutory federal income tax with the provision for income taxes on page F-36 of your Form 10-K for the year ended September 30, 2017; With reference to the nature of your tax discrete items as identified in Tables 5 and 8, please explain the appropriateness of adjusting continuing operations as well as EPS from continuing operations for this item; and With reference to Table 8, please identify the Key items included in your reconciliation of Loss from continuing operations to Adjusted income from continuing operations. In this regard, it appears that “Key items” as used herein includes tax discrete items. Please address the above bullets as they relate to the disclosures in Exhibit 99.1 of your Form 8-K dated January 29, 2018. Regarding your first bulleted comment in Comment #3, we included within our earnings release the following disclosure regarding our Outlook section: In addition, although Ashland provides forward-looking guidance for adjusted EBITDA, free cash flow and adjusted earnings per share, Ashland is not reaffirming or providing forward-looking guidance for U.S. GAAP-reported financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items that affect these metrics such as domestic and international economic, political, legislative, regulatory and legal actions. Based on your reference to Item 10(e)(1)(i)(A) of Regulation S-K and Question 102.10 of the updated Non-GAAP Compliance and Disclosure Interpretations issued on May 17, 2016 we will, in future filings, revise the foregoing disclosure as follows: In addition, although Ashland provides forward-looking guidance for adjusted EBITDA, free cash flow and adjusted earnings per share, Ashland is not reaffirming or providing forward-looking guidance for U.S. GAAP-reported financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure. Such reconciliations have not been included because Ashland is unable, without unreasonable efforts, to estimate and quantify the most directly comparable U.S. GAAP components, largely because predicting our future operating results is subject to many factors not in Ashland’s control and not readily predictable and that are not part of Ashland’s routine operating activities, including various domestic and international economic, political, legislative, regulatory and legal factors. In addition, for greater prominence of this disclosure, in future filings where an Outlook section is provided we will move this language to the beginning of the Outlook section. As a result, investors’ attention will be drawn to the qualification statements made within this disclosure before the data within the Outlook section is disclosed. Regarding your second bulleted comment in Comment #3, we respectfully submit that we have included a full reconciliation of Adjusted EBITDA to the most comparable U.S. GAAP measure in Table 7 within our earnings release disclosure. Table 5 contains supplemental information for various income statement captions, breaking down the captions by segment to highlight to investors where key items were recorded. We believe that starting with a net income reconciliation on Table 5 would be confusing to the investment community as net income is not segmented down to the reportable segment level within Ashland. In order to ensure further transparency and prominence for the complete U.S. GAAP reconciliation of Adjusted EBITDA starting from net income, in future filings we will move Table 7 in our earnings release so that it is presented before Table 5, which will illustrate the U.S. GAAP reconciliation first in our presentation. In addition, we will retitle Table 5 as “segment components of key items for applicable income statement captions” to avoid any confusion about what Table 5 is disclosing. Regarding your third bulleted comment in Comment #3, “key items” and “discrete items” as used in Table 5 of our quarterly earnings releases are defined by Ashland as follows: Key Items – The financial effects from significant transactions that, either by their nature or amount, have caused short-term fluctuations in net income and/or operating income which Ashland does not consider to most accurately reflect Ashland’s underlying business performance and trends. Further, management believes that providing supplemental information that excludes the financial effects of these items in the financial results will enhance the investor’s ability to compare financial performance between reporting periods. Discrete Items (going forward, will be referred to as Tax Specific Key Items) – Tax specific financial transactions, tax law changes or other matters that fall within the definition of key items as described above. These items relate solely to tax matters and would only be recorded within the income tax caption of the Statement of Consolidated Income. In future filings, we will rename this term “Tax Specific Key Items”. As with all key items, due to their nature, Ashland does not consider the financial effects of these tax specific key items on net income to be the most accurate reflection of Ashland’s underlying business performance and trends. In regards to the references in Table 7 and Table 8 referring readers back to Table 5, the financial effects of the key items and tax specific key items are captured in tables 5, 7 and 8 within our earnings release materials. Table 5 contains supplemental information that further breaks down captions of the income statement by segment to explain to investors where key items occurred by segment. Table 7 is the table that summarizes the U.S. GAAP reconciliations to the most comparable measure for Adjusted EBITDA on a consolidated and reporting segment basis. Table 8 is the U.S GAAP reconciliation of the diluted earnings per share (EPS) calculation that is adjusted for the identified key items and discrete items noted on Table 5. In addition, table 8 provides a supplemental reconciliation in a summarized form of the key item effects on the income statement captions for operating income and loss from continuing operations. The references made in Table 7 and Table 8 to Table 5 are intended to indicate to the investor where the supplemental segment information for key items can be located within our earnings release materials. In future filings, we will include the definitions of Key Items and Tax Specific Key Items within the disclosures in order to provide increased transparency regarding management’s use and assessment of these terms as its relates specifically to Ashland’s financial results. Regarding your fourth bulleted comment in Comment #3, the following table presents a reconciliation of discrete items (i.e. tax specific key items) within the statutory federal income tax with the provision for income taxes summary on page F-36 of the 2017 Form 10-K: Income tax computed at U.S statutory rate (35%) Foreign dividend and deemed dividend inclusions – Includes $14 million of charges that were included in the “Valvoline separation” line in previous table for response #2, which is an activity based reconciliation. In future filings of Form 10-K and Form 10-Q, we will include this table as supplemental information within the income tax discussion of Management’s Discussion and Analysis. Regarding your fifth bulleted comment in Comment #3, Ashland has adjusted for discrete items (going forward to be referred to as Tax Specific Key Items) from continuing operations and from diluted EPS in Table 5 and Table 8, respectively, as these items represent tax specific financial transactions, tax law changes or other matters that are deemed to be within the definition of key items. These key items relate only to tax specific matters and would only be recorded within the income tax caption of the Statement of Consolidated Income. As a result, these tax specific key items were termed “discrete items” within our disclosures. These tax specific key items are identified and excluded from net income using the same approach and methodology that is used for other key items. Specifically, we believe that excluding the financial effects of these items in the financial results provides investors and analysts with supplemental information to enhance their understanding of Ashland’s underlying business performance and trends as well as to better compare period-to-period financial results. Regarding your sixth bulleted comment in Comment #3, as requested, the following table presents a reconciliation of the “key items” identified in adjusting the loss from continuing operations within Table 8 of our earnings release presentation in the November Form 8-K and January Form 8-K. Ashland confirms that, as suggested in this bulleted comment, the line item for key items in our reconciliation of Loss from continuing operations to Adjusted income from continuing operations included tax discrete items (now referred to as tax specific key items). Adjusted income from continuing operations Gain on post-employment plan remeasurement As noted in Comment #3 – Third Bullet, in future filings, we will change the term “discrete items” within the income tax caption to “tax specific key items,” including within Table 5 and Table 8 of our earnings releases. In addition, in future filings we will refer readers to Table 7 (which, as noted above, will occur before Table 5 in our earnings releases) for information regarding key items and tax specific key items. We believe that the information contained in this letter is responsive to the Comments in the Comment Letter. Please acknowledge receipt of this response letter by electronic confirmation.

One letter for all the questions, without numbered answers. Read the reply
In its next report

First report after the company's reply of Feb 16, 2018: 10-Q filed May 2, 2018 ↗, against the 10-Q filed Jan 30, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Statements of Consolidated Comprehensive Income (Loss) – caption review, page M-8
SEC asked (2)
Please expand your disclosures on page M-11 to indicate how you calculated your effective tax rate (excluding key items) and why you believe this information is useful to an investor.
ASH answered

See the reply above.

In its next report

First report after the company's reply of Feb 16, 2018: 10-Q filed May 2, 2018 ↗, against the 10-Q filed Jan 30, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1 · Non GAAP Measures
SEC asked (3)
We have the following comments on your non-GAAP measures and related presentations:  With reference to your Outlook section, we note that you omit the most directly comparable GAAP measures and quantitative reconciliation with respect to your forward-looking non-GAAP guidance, but you do not provide the disclosures required when the reconciliation is omitted.
Rest of the question

Please follow the guidance in Item 10(e)(1)(i)(A) of Regulation S-K and Question 102.10 of the updated Non-GAAP Compliance and Disclosure Interpretations issued on May 17, 2016;  Please revise your reconciliations in Table 5 to begin with your most comparable GAAP measures;  Please define “key items” and “discrete items” as used in Table 5. In this regard, we note Tables 7 and 8 refer readers back to Table 5 for information regarding these items;  Please reconcile the income tax expense of discrete items to your reconciliation of the statutory federal income tax with the provision for income taxes on page F-36 of your Form 10-K for the year ended September 30, 2017;  With reference to the nature of your tax discrete items as identified in Tables 5 and 8, please explain the appropriateness of adjusting continuing operations as well as EPS from continuing operations for this item; and  With reference to Table 8, please identify the Key items included in your reconciliation of Loss from continuing operations to Adjusted income from continuing operations. In this regard, it appears that “Key items” as used herein includes tax discrete items. Please address the above bullets as they relate to the disclosures in Exhibit 99.1 of your Form 8-K dated January 29, 2018.

ASH answered

See the reply above.

In its next report

First report after the company's reply of Feb 16, 2018: 10-Q filed May 2, 2018 ↗, against the 10-Q filed Jan 30, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Management’s Discussion and Analysis, page M-1 · Diluted EPS and Adjusted Diluted EPS, page M-8
SEC asked (1)
We note the example of your prospective enhanced disclosures you will include in future filings. It appears that you have presented your key items “net of tax.” Please review the guidance set forth in Question 102.11 of the Non-GAAP Compliance and Disclosure Interpretations updated on October 17, 2017 and ensure income taxes are shown as a separate adjustment and clearly explained.
Rest of the question

Please also address our comments below as they relate to your tax specific key items.

ASH answered
Set forth below are responses from Ashland Global Holdings Inc. (“Ashland” or “we”) to the comments (the “Comments”) of the staff (the “Staff”) of the United States Securities and Exchange Commission (the “SEC”), dated March 13, 2018, concerning Ashland’s Annual Report on Form 10-K for the fiscal year ended September 30, 2017 (the “2017 Form 10-K”) and Ashland’s Form 8-K dated November 6, 2017 (the “November Form 8-K”). For your convenience, the responses set forth below have been put in the same order as the Comments were presented and repeat each Comment prior to the response. The Comments are highlighted in bold.
Rest of the letter

FORM 10-K FOR THE YEAR ENDED SEPTEMBER 30, 2017 Management’s Discussion and Analysis, page M-1 Diluted EPS and Adjusted Diluted EPS, page M-8 We note the example of your prospective enhanced disclosures you will include in future filings. It appears that you have presented your key items “net of tax.” Please review the guidance set forth in Question 102.11 of the Non-GAAP Compliance and Disclosure Interpretations updated on October 17, 2017 and ensure income taxes are shown as a separate adjustment and clearly explained. Please also address our comments below as they relate to your tax specific key items. As requested, in future filings we will identify key items before tax, separately identifying the income tax effect of all key items in its own caption when reconciling the diluted earnings per share (EPS) from continuing U.S. Securities and Exchange Commission operations and clearly explain in a footnote what this caption represents. In addition, we will identify and clearly explain (or provide a cross reference to an explanation of) the tax specific key items in the footnote disclosures within this table. The following is an example of prospective enhanced disclosures utilizing the 2017 Form 10-K filing information; we will include this enhanced disclosure in all future Form 10-Q and Form 10-K filings, beginning with our second quarter Form 10-Q filing for fiscal 2018: Diluted EPS from continuing operations (as reported) Separation, restructuring and other costs, net Net loss on acquisitions and divestitures Adjusted Diluted EPS from continuing operations (non-GAAP) (a) Represents the diluted EPS impact from the tax effect of the key items that are identified above. (b) Represents the diluted EPS impact from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. For additional explanation of these tax specific key items see the income tax expense (benefit) caption discussion in the MD&A. Statements of Consolidated Comprehensive Income (Loss) – caption review, page M-8 We have reviewed your expanded disclosures regarding the calculation of your effective tax rate (excluding key items) and have the following additional comments: Please present a schedule that clearly identifies the pre-tax dollar amounts of each key item or provide an appropriate cross-reference; and Ensure your Management’s Discussion and Analysis fully discusses the nature of your valuation allowance, foreign dividends and Valvoline tax specific adjustments such that readers fully understand the nature and basis for each adjustment. As requested, in future filings we will separately identify the pre-tax dollar amounts of each key item by including a reference within the new table disclosure (Response #2 in letter dated February 16, 2018) in the income tax expense (benefit) caption review to our Adjusted EBITDA table where we will enhance our disclosures to clearly illustrate these total pre-tax dollar effects. In addition, we will fully discuss the nature of each significant tax specific key item identified, including adjustments for valuation allowances, foreign dividends and Valvoline tax specific adjustments or other significant adjustments that can occur. The following is an example of prospective enhanced disclosures utilizing the 2017 Form 10-K filing information for fiscal 2017. In all future Form 10-Q and Form 10-K filings we will include a full description of all these tax specific key items for each period presented within the filing. The 2017 effective tax rate was primarily impacted by the following three tax specific key items: Foreign dividends - $87 million tax expense Valuation allowance - $21 million tax benefit Valvoline separation - $17 million tax expense The foreign dividends adjustment relates to a significant deemed dividend inclusion in the U.S. This deemed dividend transaction allowed Ashland to utilize foreign tax credit carryforwards which may have otherwise expired. This transaction was driven in part by projected changes to Ashland’s business and tax profile as a result of the Valvoline separation and is not the type of transaction that would be routinely executed as part of Ashland’s underlying business. The valuation allowance adjustment relates to the impact of the above foreign dividend discussion which served as a source of income for the reversal of a net $21 million foreign tax credit valuation allowance. The Valvoline separation charge relates to various tax impacts of the Valvoline separation including state tax costs, foreign tax costs and other tax account adjustments. These charges are not related to Ashland’s underlying business. For additional information on the effect that these adjustments had on EPS during 2017 see the Diluted EPS from continuing operations table adjusted for key items earlier in the MD&A analysis. It appears that you have presented your key items “net of tax”. Please review the guidance set forth in Question 102.11 of the Non-GAAP Compliance and Disclosure Interpretations updated on October 17, 2017 and ensure income taxes are shown as a separate adjustment and clearly explained. As requested, in future filings we will identify key items before tax, separately identifying the income tax effect of all key items in its own caption when reconciling the diluted EPS from continuing operations and clearly explain in a footnote what this caption represents. In addition, in the footnote disclosures within this table we will identify and clearly explain the tax specific key items. We will include a table in this presentation similar to the example table provided to you in Response #1 of this letter. Please fully discuss the nature of your valuation allowance, foreign dividends and Valvoline tax specific adjustments such that readers fully understand the nature and basis for each adjustment. As requested, in future filings we will separately identify within the income tax expense (benefit) caption of the Statement of Consolidated Comprehensive Income (Loss) caption review the pre-tax dollar amounts of each tax specific key item. In addition, we will fully discuss the nature of each significant tax specific key item identified, including any adjustments for valuation allowances, foreign dividends and Valvoline tax specific adjustments or other significant adjustments that can occur. We will include an explanation in this presentation similar to the example table provided to you in Response #2 of this letter. We believe that the information contained in this letter is responsive to the Comments in the Comment Letter. Please acknowledge receipt of this response letter by electronic confirmation.

One letter for all the questions, without numbered answers. Read the reply
In its next report

First report after the company's reply of Mar 20, 2018: 10-Q filed May 2, 2018 ↗, against the 10-Q filed Jan 30, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Statements of Consolidated Comprehensive Income (Loss) – caption review, page M-8
SEC asked (2)
We have reviewed your expanded disclosures regarding the calculation of your effective tax rate (excluding key items) and have the following additional comments:  Please present a schedule that clearly identifies the pre-tax dollar amounts of each key item or provide an appropriate cross-reference; and  Ensure your Management’s Discussion and Analysis fully discusses the nature of your valuation allowance, foreign
Rest of the question

dividends and Valvoline tax specific adjustments such that readers fully understand the nature and basis for each adjustment.

ASH answered

See the reply above.

In its next report

First report after the company's reply of Mar 20, 2018: 10-Q filed May 2, 2018 ↗, against the 10-Q filed Jan 30, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1 · Non GAAP Measures
SEC asked (3)
It appears that you have presented your key items “net of tax”. Please review the separate adjustment and clearly explained.
ASH answered

See the reply above.

In its next report

First report after the company's reply of Mar 20, 2018: 10-Q filed May 2, 2018 ↗, against the 10-Q filed Jan 30, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1 · Non GAAP Measures
SEC asked (4)
Please fully discuss the nature of your valuation allowance, foreign dividends and Valvoline tax specific adjustments such that readers fully understand the nature and basis for each adjustment.
ASH answered

See the reply above.

In its next report

First report after the company's reply of Mar 20, 2018: 10-Q filed May 2, 2018 ↗, against the 10-Q filed Jan 30, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2018-03-22

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 15 letters filed since 2018-02-07. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ASH/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.